NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Receives $34.75 Consensus Price Target from Analysts

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) has earned an average recommendation of “Moderate Buy” from the six research firms that are covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $34.75.

A number of equities analysts have recently weighed in on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of NRx Pharmaceuticals in a research note on Wednesday, October 8th. Wall Street Zen lowered shares of NRx Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday. HC Wainwright reissued a “buy” rating and set a $40.00 price objective on shares of NRx Pharmaceuticals in a research note on Thursday, October 16th. D. Boral Capital restated a “buy” rating and issued a $34.00 price objective on shares of NRx Pharmaceuticals in a research report on Monday, November 10th. Finally, Ascendiant Capital Markets raised their price target on NRx Pharmaceuticals from $46.00 to $47.00 and gave the stock a “buy” rating in a research note on Thursday, October 30th.

NRx Pharmaceuticals Price Performance

Shares of NRXP opened at $2.49 on Thursday. The business has a 50-day moving average of $3.02 and a 200-day moving average of $2.88. NRx Pharmaceuticals has a 1 year low of $1.13 and a 1 year high of $6.01. The company has a market capitalization of $49.33 million, a price-to-earnings ratio of -1.06 and a beta of 1.76.

NRx Pharmaceuticals (NASDAQ:NRXP) last issued its quarterly earnings data on Friday, November 14th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.07). The company had revenue of $0.24 million during the quarter, compared to analysts’ expectations of $6.83 million. As a group, sell-side analysts anticipate that NRx Pharmaceuticals will post -1.75 EPS for the current year.

Hedge Funds Weigh In On NRx Pharmaceuticals

A number of institutional investors have recently made changes to their positions in NRXP. Ethos Financial Group LLC acquired a new stake in NRx Pharmaceuticals in the third quarter valued at $39,000. One Wealth Management Investment & Advisory Services LLC increased its stake in NRx Pharmaceuticals by 86.1% during the third quarter. One Wealth Management Investment & Advisory Services LLC now owns 27,991 shares of the company’s stock valued at $92,000 after purchasing an additional 12,950 shares during the last quarter. Two Sigma Investments LP increased its position in NRx Pharmaceuticals by 66.4% in the 3rd quarter. Two Sigma Investments LP now owns 52,332 shares of the company’s stock valued at $173,000 after acquiring an additional 20,880 shares in the last quarter. Geode Capital Management LLC raised its position in shares of NRx Pharmaceuticals by 27.9% during the second quarter. Geode Capital Management LLC now owns 172,255 shares of the company’s stock worth $562,000 after acquiring an additional 37,598 shares during the last quarter. Finally, AdvisorShares Investments LLC grew its holdings in NRx Pharmaceuticals by 29.7% during the 3rd quarter. AdvisorShares Investments LLC now owns 342,136 shares of the company’s stock worth $1,129,000 after acquiring an additional 78,339 shares during the period. 4.27% of the stock is owned by institutional investors and hedge funds.

NRx Pharmaceuticals Company Profile

NRx Pharmaceuticals, Inc, a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.